Monthly Prescribing Reference

Simponi Aria Approved for Polyarticular JIA, Pediatric Psoriatic Arthritis

Simponi Aria is available as a 50mg/4mL strength solution for IV infusion; it is administered as a 30-minute infusion. The Food and Drug Administration (FDA) has approved Simponi Aria® (golimumab; ...
Healio

Intravenous golimumab shows long-term benefit for juvenile idiopathic arthritis

Please provide your email address to receive an email when new articles are posted on . Intravenous golimumab for JIA maintained an acceptable risk-benefit profile in a long-term extension study. The ...
Business Insider

SIMPONI ARIA® (golimumab) Approved by the U.S. Food and Drug Administration for Active Polyarticular Juvenile Idiopathic Arthritis and Extension of Its Active Psoriatic ...

HORSHAM, Pa., Sept. 30, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA ® ...
The Business Journals

Janssen seeks OK for intravenous Simponi

Johnson & Johnson (NYSE:JNJ) subsidiary Janssen Biotech of Horsham, Pa., is seeking Food and Drug Administration approval for an intravenous version of its Simponi treatment for rheumatoid arthritis.
Reuters

Big-profile Schering arthritis drug wins Canada nod

NEW YORK, April 13 (Reuters) - Johnson & Johnson and Schering-Plough Corp said on Monday that Canadian regulators had approved use of their experimental once-monthly drug Simponi to treat moderate to ...